Article Text

AB0812 Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Review of 63 Cases
  1. D. Amri1,
  2. K. Baccouche1,
  3. K. Zahra2,
  4. B. Monia1,
  5. S. Belghali1,
  6. N. Elamri1,
  7. Z. Alaya1,
  8. H. Zeglaoui1,
  9. E. Bouajina1
  1. 1Rheumatology
  2. 2Hematology, Farhat Hached Hospital, Sousse, Tunisia


Background Multiple myeloma is a malignant disorder in which plasma cells accumulate in the bone marrow and produce an entire immunoglobulin (usually IgG or IgA) or only immunoglobulin light chains (kappa or lambda). Multiple myeloma accounts for approximately 10% of hematologic cancers and 1% of all cancers. In recent years there is huge improvement in treatment of patients with multiple myeloma. The milestone of these improvement is the Autologous hematopoietic stem cell transplantation

Methods We analyzed results of 63 consecutive patients (16 male and 47 female) of MM who underwent Autologous hematopoietic stem cell transplantation (ASCT).

Results A review of 63 cases of multiple myeloma seen from 2006 through 2015 revealed that The median age was 59,1 years (range: 38–80) and that 25% of them were male. Inital findings were bone pain in 73,8% of patients, anemia in 14%, renal insufficiency in 11% and hypercalcemia in 34,9%. Proteinuria was noted in 10% and Bence Jones proteinuria was identified in 5,2%. Skeletal roentgenographic abnormalities were seen in 78%. Serum proteinelectrophoresis showed a spike in 83% and hypogammaglobulinemia in 17%. Immunoelectrophoresis of the serum revealed a monoclonal heavy chain in 80% and a monoclonal light chain in the serum, in 5.2% (Bence Jones proteinemia). ASCT was performed in 15 patient (age <65ans); Post ASCT 47,1% of patients achieved complete reponse, 24,2% had very good partial response (VGPR), and 38.7% had partial response (PR).

Conclusions Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.